Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease

Clin Infect Dis. 2023 Dec 30:ciad785. doi: 10.1093/cid/ciad785. Online ahead of print.

Emmanuel Lafont¹, Damien Blez², Marc-Antoine Bildan³, David Veyer^{4

5

6}, Hélène Péré^{4

5

6}, Julien Puech⁴, Benjamin Kably⁷, Geoffrey Cheminet¹, Jacques Pouchot^{1

6}, Eric Thervet^{6

8}, Gilles Peytavin^{6

9}, Helene Lazareth^{6

8}

¹ Department of Internal Medicine, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
² Bacteriology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
³ Pharmacology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Virology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁵ UMR 1137, IAME, Université Paris Cité, Paris, France.
⁶ Université Paris Cité, Paris, France.
⁷ Pharmacology Unit and DMU BIOPHYGEN, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, France; INSERM PARCC UMRS970, Paris, France.
⁸ Nephrology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁹ Pharmacology Department, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France.

No abstract available

Keywords: COVID-19; Nirmatrelvir/ritonavir; Omicron; SARS-CoV-2; chronic kidney disease; hemodialysis; pharmacokinetics.